Conzip Addiction Hotline

24/7, Toll-Free, Confidential

Conzip is an extended-release version of the synthetic opioid tramadol. Conzip is indicated for the management of moderate to severe chronic pain that requires around-the-clock treatment.

Conzip achieves its pain-relieving effects by activating opioid receptors in the body and inhibiting the reuptake of the neurotransmitters norepinephrine and serotonin. The exact mechanism of action of Conzip is unknown. Conzip is converted into desmetramadol in the body. Desmetramadol is an active metabolite of tramadol, and it’s a more potent opioid.

Conzip should not be administered to patients who are at risk of suicide. The amount of Conzip necessary to overdose depends on several factors. In general, patients should not exceed 300 mg of any tramadol product in a 24-hour period.

Conzip is considered equally potent when compared to codeine and pethidine and is one-tenth as strong as morphine.

Common side effects of Conzip include nausea, dizziness, sweating and itching. These types of symptoms are common among most opioids.

Conzip Overdose
The primary symptoms of Conzip overdose include severe respiratory depression, decreased level of consciousness and constricted pupils. These three symptoms are referred to as the “opioid overdose triad.” Of these, respiratory depression is the most life-threatening.

Conzip is a powerful central nervous system depressant. It suppresses the subconscious instinct to breathe by acting on the brainstem. During an overdose, the brainstem may lose its ability to analyze carbon dioxide levels in the blood. Under normal circumstances, the brainstem triggers the lungs to breathe when carbon dioxide levels become elevated. In the event of an overdose, this mechanism becomes disrupted, potentially leading to toxic carbon dioxide levels, oxygen deprivation, coma and death.

In the event of an overdose, the pupils may become maximally constricted or “pinpointed.” Pupils will refuse to dilate, even when exposed to direct light. The only exception to this is in the event of severe oxygen deprivation (hypoxia). As the brain becomes starved of oxygen, the pupils will likely change from pinpoint to full dilation.

Decreased levels of consciousness are described as somnolence progressing to stupor or coma. The individual may deteriorate rapidly from responding in full sentences to being entirely unaware of their surroundings.

Other clinical presentations of acute Conzip overdose include skeletal muscle flaccidity, pulmonary edema, heart arrhythmias, cold and clammy skin, bradycardia (slow heart rate), airway obstruction and hypotension (low blood pressure).

Conzip Overdose
The amount of Conzip necessary to overdose depends on each patient’s body weight, age, opioid tolerance, genetic tendencies, kidney and liver function, and overall physical health.

Patients should not exceed more than 300 mg of Conzip in a single day. Non-opioid tolerant patients should start with a dose of 100 mg per day. This dose can be increased by increments of 100 mg every five days.

In the event of a Conzip overdose, respiratory depression is the most pressing concern. The priority will be to secure and protect the patient’s airway. Assisted or controlled ventilation may be needed. If the patient is conscious, a bag-valve mask may be used to assist ventilation. If the patient is unconscious, an endotracheal tube may need to be inserted to secure the airway and prevent it from becoming obstructed.

Oxygen therapy will likely be administered to help support oxygenation and address the onset of pulmonary edema. Vasopressors may be used to manage cardiovascular depression. In the event of heart arrhythmias or cardiac arrest, advanced life-support measures including CPR and shock treatment may be necessary.

In the event of clinically significant respiratory depression, the administration of the opioid antagonist naloxone may be necessary to reverse the effects of Conzip. Naloxone rapidly reverses the effects of opioids like Conzip by breaking its bonds with receptors in the body.

Naloxone should not be administered unless clinically significant respiratory depression is evident. The premature administration of naloxone can make the patient’s condition worse. The risk of seizures increases upon administration of naloxone as treatment for Conzip overdose.

Several doses of naloxone may be needed in severe overdose cases. Intervals of two to three minutes should be allowed between doses. The duration of naloxone is significantly shorter than that of Conzip. The patient should be monitored closely for the first 24 to 48 hours following administration for the return of potentially life-threatening respiratory depression. In opioid-dependent patients, the administration of naloxone can precipitate the onset of severe post-acute opioid withdrawals.

If you or someone you love is struggling with an opioid misuse disorder, The Recovery Village is available to answer any questions you may have. Visit them at or call them toll-free at 855-548-9825 for more information about recovery resources in your area.

Medical Disclaimer: The Recovery Village aims to improve the quality of life for people struggling with a substance use or mental health disorder with fact-based content about the nature of behavioral health conditions, treatment options and their related outcomes. We publish material that is researched, cited, edited and reviewed by licensed medical professionals. The information we provide is not intended to be a substitute for professional medical advice, diagnosis or treatment. It should not be used in place of the advice of your physician or other qualified healthcare provider.